ClinicalTrials.gg
Status unknownNCT05470049Updated Jul 22, 2022

A Clinical Study of the Combination of SHR8554 Injection and SHR0410 Injection for the Treatment of Pain After Abdominal Surgery.

A Phase 2 interventional study of SHR8554 Injection and SHR0410 Injection and SHR8554 Injection and SHR0410 Injection in Pain, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. — none open to participants now, none under way, none of them phase 3. Pain · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
7th of 15
108 · median 96
Started
2022
with 3 others
Phase 2
4 of 15
none open now
Registered
10th of 15
by date

Among the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by planned enrollment, is one of 4 that started in 2022, is one of 4 in phase 2, and was the 10th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. is open now. The open studies under Pain, anywhere →

Where they have run

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Pain by Jiangsu HengRui Medicine Co., Ltd. as a file.
02

Study summary

The primary objective is to evaluate the analgesic efficacy of the combination of SHR8554 injection and SHR0410 injection compared with SHR8554 injection in patients with acute postoperative pain following abdominal surgery

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written
  2. Subjects requiring elective general anesthesia abdominal surgery
  3. Conform to the ASA Physical Status Classification

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of difficult airway
  2. Subjects with a history of reflux esophagitis
  3. Subjects with a history of mental illness
  4. Subjects with poor blood pressure control
  5. Random blood glucose ≥11.1mmol/L
  6. Subjects with abnormal liver function
  7. allergies to opioids and other medications that may be used during the trial
  8. The investigators determined that other conditions were inappropriate for participation in this clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Treatment group A: SHR8554 Injection and SHR0410 Injection

    Drug: SHR8554 Injection and SHR0410 Injection

  • Experimental
    Treatment group B: SHR8554 Injection and SHR0410 Injection

    Drug: SHR8554 Injection and SHR0410 Injection

  • Placebo comparator
    Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection

    Drug: SHR8554 Injection and Placebo for SHR0410 Injection

Interventions

  • DrugSHR8554 Injection and SHR0410 Injection

    Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose

  • DrugSHR8554 Injection and SHR0410 Injection

    Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose

  • DrugSHR8554 Injection and Placebo for SHR0410 Injection

    Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection

06

What researchers measure

Primary outcomes

  1. the Sum of Pain Intensity Differences in Pain Score Over 24 Hours

    Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 24 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (24 hours) to yield values on the 0-10 NPRS.

    Time frame: 24-hours

Secondary outcomes

  1. the Sum of Pain Intensity Differences in Pain Score Over 6、12、12-24 Hours

    time weighted sum of pain intensity differences (SPID) divided by a constant (6、12、12-24 hours) to yield values on the 0-10 NPRS.

    Time frame: 6-hours、12-hours、12-24 hours

  2. Time of first use of remedial analgesic medication

    The first time to use remedial analgesic medication for injection

    Time frame: 24-hours

  3. Cumulative use of remedial analgesics from 0h to 24h

    Cumulative use of remedial analgesic medication

    Time frame: 24-hours

  4. Participant ' satisfaction score for analgesia treatment

    Participants recalled the postoperative analgesia effect and rated their satisfaction on a scale of 0 to 10, with 0 representing dissatisfied and 10 representing very satisfied.

    Time frame: 24-hours

  5. Investigator satisfaction score for analgesia treatment

    Postoperative analgesia was evaluated by investigators.The scale ranges from 0 to 10, with 0 being dissatisfied and 10 being very satisfied.

    Time frame: 24-hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2022; primary completion for Nov 2022, 3 months later.

Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 3 months is below that.

Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2022
First posted
Jul 22, 2022
StartEst.
Aug 1, 2022
Primary completionEst.
Nov 1, 2022
CompletionEst.
Nov 30, 2022
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05470049
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Aug 1, 2022 (estimated)
Primary completion
Nov 1, 2022 (estimated)
Completion
Nov 30, 2022 (estimated)
Last update
Jul 22, 2022

Study contacts

Qin Liu
Contact
qin.liu@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion